

## **PharmaMar will present at ESMO results of the phase III CORAIL study with lurbinectedin in platinum-resistant Ovarian Cancer**

- **During the ESMO Congress, data will be presented in an oral session regarding the observed progression-free survival (PFS) of patients with platinum-resistant ovarian cancer treated with lurbinectedin, versus Doxil<sup>®</sup> (PLD) or topotecan, as well as the observed safety profile**
- **Data will also be presented at ESMO on the quality of life of Advanced Soft Tissue Sarcoma (ASTS) patients treated with Yondelis<sup>®</sup>**

**Madrid, 18<sup>th</sup> of October 2018.-** During the congress of the European Society of Medical Oncology (ESMO), that will be held from the 19<sup>th</sup> to the 23<sup>rd</sup> of October in Munich, Germany, PharmaMar's (MSE:PHM) Zepsyre<sup>®</sup> (lurbinectedin) abstract #9320 entitled "*Phase III trial of Lurbinectedin versus PLD or Topotecan in platinum-resistant ovarian cancer patients: Results of CORAIL trial*" will be presented orally on the 19<sup>th</sup> of October.

**Dr. Ali Zeaiter**, Director of Clinical Development of the Oncology Business Unit at PharmaMar explains: "*While we are disappointed that the CORAIL trial didn't meet its primary endpoint of PFS, the data obtained support that lurbinectedin has activity in platinum-resistant Ovarian Cancer.*"

Data obtained from other PharmaMar compounds of marine origin, lurbinectedin and Yondelis<sup>®</sup> (trabectedin) will also be presented. These include four other posters with the latest advances in the clinical development of trabectedin, including the results of the randomized phase III (TSAR) study evaluating the quality of life of patients with Advanced Soft Tissue Sarcoma (ASTS).

The studies that will be presented during the ESMO 2018 Congress are available at: <https://cslide.ctimeetingtech.com/library/esmo/browse/search>

## Lurbinectedin

- **Phase III trial of Lurbinectedin versus PLD or Topotecan in platinum-resistant ovarian cancer patients: Results of CORAIL trial (#9320)**

Oral presentation - 19.10.2018, 14:00 - 15:15, in Hall A1 - Room 15.

Principal Author: S. Gaillard, Baltimore, US.

- **SAKK 17/16 - Lurbinectedin monotherapy in patients with progressive malignant pleural mesothelioma: A multicenter, single-arm phase II trial (#1817TiP)**

Poster - 20.10.2018, 13:30 Hall A3 - Poster Area - Networking Hub

Principal Author: Y. Metaxas. Chur, Switzerland.

## Yondelis® (trabectedin)

- **Health-related quality of life in patients with advanced soft tissue sarcoma (ASTS): Results from the TSAR randomized phase III trial of the French Sarcoma Group (#1604PD)**

Poster Discussion - Sarcoma. 22.10.2018, 11:00 - 12:15, in Hall B3 - Room 23

Principal Author: Axel Le Cesne, Villejuif, France.

- **Quality of Life in patients with soft tissue sarcoma undergoing palliative treatment - A multicenter, cluster-randomized trial within the German Interdisciplinary Sarcoma Group, GISG-12 (#1606PD)**

Poster Discussion - Sarcoma. 22.10.2018, 11:00 - 12:15, in Hall B3 - Room 23

Principal Author: Leopold Hentschel, Dresden, Germany.

- **Trabectedin and radiotherapy in advanced sarcoma: experience of a Reference Center (#1626P)**

Poster - 22.10.2018, 12:45 - 13:45, in Hall A3 - Poster Area Networking Hub

Principal Author: Javier Martín-Broto, Seville, Spain.

- **Trabectedin plus pegylated liposomal doxorubicin (PLD) in patients with platinum-sensitive recurrent ovarian cancer (PSROC) regardless of prior use of antiangiogenics: First results of an observational, prospective study (#987P)**

Poster - 20.10.2018, 12:30 - 13:30, in Hall A3 - Poster Area Networking Hub  
Principal Author: Sandro Pignata, Naples, Italy.

#### **Legal warning**

This press release does not constitute an offer to sell or the solicitation of an offer to buy securities, and shall not constitute an offer, solicitation or sale in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of that jurisdiction.

#### **About PharmaMar**

Headquartered in Madrid, PharmaMar is a biopharmaceutical company, focused on oncology and committed to research and development which takes its inspiration from the sea to discover molecules with antitumor activity. It is a company that seeks innovative products to provide healthcare professionals with new tools to treat cancer. Its commitment to patients and to research has made it one of the world leaders in the discovery of antitumor drugs of marine origin.

PharmaMar has a pipeline of drug candidates and a robust R&D oncology program. It develops and commercializes Yondelis® in Europe and has other clinical-stage programs under development for several types of solid cancers: lurbinectedin (PM1183), PM184 and PM14. With subsidiaries in Germany, Italy, France, Switzerland, Belgium, Austria and the United States. PharmaMar wholly owns other companies: GENOMICA, a molecular diagnostics company; Sylentis, dedicated to researching therapeutic applications of gene silencing (RNAi); and a chemical enterprise, Zelnova Zeltia. To learn more about PharmaMar, please visit us at [www.pharmamar.com](http://www.pharmamar.com).

#### **About YONDELIS® (trabectedin)**

YONDELIS® (trabectedin) is a multimodal, synthetically produced antitumor agent, originally derived from the sea squirt, *Ecteinascidia turbinata*. The drug exerts its activity by targeting the transcriptional machinery and impairing DNA repair. It is approved in close to 80 countries in North America, Europe, South America and Asia for the treatment of advanced soft tissue sarcomas as a single-agent and for relapsed ovarian cancer in combination with DOXIL®/CAELYX® (doxorubicin HCl liposome injection) in the European Union. Under a licensing agreement with PharmaMar, Janssen Products, L.P. has the rights to develop and sell YONDELIS® globally except in Europe, where PharmaMar holds the rights, and in Japan, where PharmaMar has granted a license to Taiho Pharmaceuticals.

#### **About lurbinectedin**

Lurbinectedin (PM1183) is a compound under clinical investigation. It is an inhibitor of RNA polymerase II. This enzyme is essential for the transcription process that is over-activated in tumors with transcription addiction.

#### **Media Contact:**

Alfonso Ortín – Communications Director [aortin@pharmamar.com](mailto:aortin@pharmamar.com) Mobile: +34 609493127  
Miguel Martínez-Cava – Digital Communication Manager [mmartinez-cava@pharmamar.com](mailto:mmartinez-cava@pharmamar.com) Mobile: +34 606597464  
Phone: +34 918466000



**Investor Relations:**

Phone: +34 914444500 / +34 902 10 19 00

Email: [investorrelations@pharmamar.com](mailto:investorrelations@pharmamar.com)

Or please visit our website at [www.pharmamar.com](http://www.pharmamar.com)